REPORTING SEASON: CSL Limited (CSL)
Brought to you by CommSec
Figure 1: CSL Ltd 12 month chart
Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today.
The CSL Group reported a 3.7% rise in sales with total revenue (includes royalties) increasing by 4.8% to US$2.574 billion.
The company did take a hit in this result due to the one-off US antitrust class action litigation settlement of US$64 million.
The settlement was no surprise to investors as the payment occurred in October 2013 and was in relation to artificial price increases in the US.
Management said the result was solid apart from the settlement and CSL’s underlying operations remained strong and global demand for its plasma therapies and its pipeline of new product will boost future revenues.
CSL Behring sales grew by 6%* to US$2.4 billion and its immunoglobulin product sales lifted by 7%*.While its haemophilia product sales fell by 4%* CSL did receive a boost to income from its specialty products sales up 16%*.
CSL royalties over the period increase to US$78.7 million up from US$68.4 million (Y/Y) CSL will pay a half year dividend of US$0.53.
The said it expects FY14 after tax profit growth of around 7% and CSL will continue its current A$950 million share buyback that is now 22% completed.